SCHEMBL2695042

SCHEMBL2695042

Cc1cc(Nc2cc(N(C)c3cncnc3)c(C(N)=O)cn2)ccc1C(=O)N(C)C

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPK9 P45984 2/20 0.46
▸ MAPK10 P53779 2/20 0.46
▸ JAK2 O60674 3/20 0.40
▸ JAK1 P23458 3/20 0.40
▸ TYK2 P29597 3/20 0.40
▸ NNMT P40261 1/20 0.39
▸ CDK2 P24941 1/20 0.39
▸ JAK3 P52333 2/20 0.37
▸ IRAK4 Q9NWZ3 2/20 0.37
▸ SYK P43405 4/20 0.37
▸ CSF1R P07333 3/20 0.36
▸ PDE4B Q07343 1/20 0.36
▸ PTK2 Q05397 1/20 0.35
▸ KIT P10721 1/20 0.35
▸ FLT3 P36888 1/20 0.35
▸ MAPK13 O15264 1/20 0.34
▸ MAPK12 P53778 1/20 0.34
▸ MAPK11 Q15759 1/20 0.34
▸ MAPK14 Q16539 1/20 0.34
▸ CYP1A2 P05177 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2693252 0.89 JAK1 (0.44) MAPK9MAPK10JAK2JAK1TYK2
SCHEMBL2695046 0.82 JAK3 (0.55) MAPK9MAPK10JAK2JAK1TYK2
SCHEMBL2694919 0.81 CSF1R (0.47) MAPK9MAPK10IRAK4SYKCSF1R
SCHEMBL2694914 0.78 MAPK9 (0.52) MAPK9MAPK10JAK2JAK1TYK2
SCHEMBL2697486 0.78 MAPK9 (0.42) MAPK9MAPK10JAK2JAK1TYK2
SCHEMBL2696064 0.78 MAPK9 (0.42) MAPK9MAPK10JAK2JAK1TYK2
SCHEMBL2696692 0.76 JAK2 (0.41) MAPK9MAPK10JAK2JAK1TYK2
SCHEMBL2696149 0.74 JAK3 (0.70) MAPK9MAPK10JAK2JAK1TYK2
SCHEMBL2696135 0.74 MAPK9 (0.55) MAPK9MAPK10JAK2JAK1TYK2
SCHEMBL2693260 0.73 JAK3 (0.52) MAPK9MAPK10JAK2JAK1TYK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150353495-A1 NICOTINAMIDES AS JAK KINASE MODULATORS ALEXION PHARMACEUTICALS, INC. 2015-12-10 — — US claimed
US-20120108566-A1 NICOTINAMIDES AS JAK KINASE MODULATORS PORTOLA PHARMACEUTICALS, INC. (US) 2012-05-03 — — US claimed
EP-2975027-A1 NICOTINAMIDES AS JAK KINASE MODULATORS Portola Pharmaceuticals, Inc. (US) 2016-01-20 — — EP disclosed
US-20150353495-A1 NICOTINAMIDES AS JAK KINASE MODULATORS ALEXION PHARMACEUTICALS, INC. 2015-12-10 — — US disclosed
US-9102625-B2 Nicotinamides as JAK kinase modulators PORTOLA PHARMACEUTICALS, INC. (US) 2015-08-11 — — US disclosed
EP-2635557-A2 NICOTINAMIDES AS JAK KINASE MODULATORS Portola Pharmaceuticals, Inc. (US) 2013-09-11 — — EP disclosed
WO-2012061428-A2 NICOTINAMIDES AS JAK KINASE MODULATORS PORTOLA PHARMACEUTICALS, INC. (US) 2012-05-10 — — WO disclosed
US-20120108566-A1 NICOTINAMIDES AS JAK KINASE MODULATORS PORTOLA PHARMACEUTICALS, INC. (US) 2012-05-03 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150353495-A1 NICOTINAMIDES AS JAK KINASE MODULATORS JAK2, JAK1, NADK MAPK9 124/4885MAPK10 260/4885JAK2 1/4885
US-20120108566-A1 NICOTINAMIDES AS JAK KINASE MODULATORS JAK2, JAK1, NADK MAPK9 124/4885MAPK10 260/4885JAK2 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback